Search

The article provides information on Winrevair (sotatercept-csrk), a drug indicated for the treatment pulmonary arterial hypertension in adults, from Merck Sharp & Dohme LLC.

The article highlights advancements in CNS (central nervous system) drug delivery, particularly focusing on overcoming the challenges posed by the blood-brain barrier (BBB) through innovative technologies such as neurotropic viruses, receptor-mediated transcytosis, and peptide shuttles. It discusses the potential of these approaches in facilitating the delivery of therapeutics for neurodegenerative diseases and glioblastomas.

The article presents trending dermatologic studies. They include "Causal Effects of Lipids-Related Metabolites on Androgenic Alopecia: A Mendelian Randomization Study," "A Cross-sectional Review of Contact Allergens in Popular Self-Tanning Products," and "Real-World Experience of Vitiligo Patients: A Retrospective Chart Review."

The article delves into the critical role of biosimilar analytical assessments, focusing on demonstrating biosimilarity and interchangeability with the reference biologic. It emphasizes the importance of developing a robust analytical strategy for biosimilar studies to navigate regulatory challenges and ensure safe, effective, and affordable biological treatments.

The article reports on the approval of Fasenra from AstraZeneca by the U.S. Food and Drug Administration (FDA) for the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA). Topics mentioned include the use of Fasenra as a maintenance drug for adult-onset severe eosinophilic asthma, the common symptoms of EGPA and the benefits of Fasenra to patients.

The article focuses on KalVista Pharmaceuticals Inc.'s announcement that the FDA (U.S. Food and Drug Administration) has accepted a New Drug Application (NDA) for sebetralstat, an oral plasma kallikrein inhibitor intended to treat hereditary angioedema (HAE) attacks in patients aged 12 and older. It highlights the promising results from the KONFIDENT phase 3 clinical trial and the ongoing KONFIDENT-S trial, which demonstrated significant symptom relief from sebetralstat.

The article reports that Lilly has introduced a single-dose vial version of Zepbound (tirzepatide) for self-pay patients. Topics include the clinical efficacy of Zepbound in aiding significant weight loss and reducing type 2 diabetes risk, the pricing structure of the self-pay option, and the availability of Zepbound in various doses and formats for treating obesity and related conditions.

The article presents the discussion on FDA's complete response letter to Novo Nordisk's application for the once-weekly basal insulin icodec. Topics include requesting additional information on its manufacturing process and use for type 1 diabetes; and prevalence and management of type 1 diabetes, the clinical trial data supporting the application, and regulatory feedback on insulin icodec's safety and efficacy.

The article announces the Food and Drug Administration (FDA) approval of Genentech's Vabysmo as a 6.0 mg prefilled syringe for treating wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. It also discusses the drug's mechanism of action targeting angiopoietin-2 and VEGF-A, its substantial sales growth, and the availability of a copay assistance program to mitigate patient costs.

The article reports on the acceptance by the U.S. Food and Drug Administration (FDA) of a biologics license application (BLA) seeking approval of nivolumab (Opdivo) co-formulated with Halozyme Therapeutics' proprietary recombinant human hyaluronidase for the treatment of patients with solid tumors. Topics discussed include study findings that supported the BLA submission, safety profile for subcutaneous nivolumab, and the occurrence of deaths during the study.

The article provides information on adagrasib, a drug indicated for the treatment of adults with KRAS G12C-mutated, locally advanced or metastatic non-small cell lung cancer (NSCLC). Topics discussed include data which supported the approval of adagrasib by the U.S. Food and Drug Administration (FDA) on December 12, 2022, how it is administered, and how to manage associated adverse events.

The article highlights Breyanzi's inclusion in NCCN guidelines as a third-line treatment for relapsed or refractory follicular lymphoma. Breyanzi, a CD19-directed CAR T cell therapy, demonstrated high response rates in the TRANSCEND FL study, presenting a significant advancement in treating this lymphoma subtype.

The article offers information on the administrative issues delaying the FDA's decision on Moderna's investigational respiratory syncytial virus (RSV) vaccine. Topics include the delay in completing the review of the biologics license application (BLA) for mRNA-1345, the vaccine's review at the CDC's Advisory Committee on Immunization Practices (ACIP) meeting in June 2024, RSV and its impact on older adults, and plans for launching the vaccine in various markets.

The article offers information on the real-world data showing that Orladeyo (berotralstat) can reduce healthcare resource utilization for patients with hereditary angioedema (HAE). Topics include the rare genetic condition HAE, the approval and cost of Orladeyo, a retrospective real-world study analyzing the claims data of 260 U.S. patients with HAE, reductions in all-cause hospitalizations and emergency room visits following Orladeyo initiation.

The article features urology-related developments in the U.S. as of May 1, 2024. It cites the Food and Drug Administration's (FDA) granting of 510 (k) clearance to the RenaFlex single-use flexible ureteroscope system from Olympus for treatment of urinary diseases like kidney stones. Also noted is Teleflex Incorporated's full market launch of the unified UroLift 2 System with Advanced Tissue Control (UroLift 2 ATC) for treatment of benign prostatic hyperplasia (BPH).

The article discusses the U.S. Food and Drug Administration (FDA) approval of Selarsdi, a biosimilar to Stelara, for treating various conditions, highlighting Alvotech's second biosimilar approval. Topics include ustekinumab's therapeutic applications, Alvotech's biosimilar development success, and its impact on the psoriasis treatment market.

The article evaluates the Rexulti drug from Otsuka Pharmaceutical Co, Ltd. used for treatment of agitation associated with dementia due to Alzheimer's disease.

The article focuses on the U.S. Food and Drug Administration (FDA) has approved Elahere for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients with prior systemic treatment. It reports that the approval was based on data from the confirmatory phase 3 MIRASOL trial, showing a reduction in death and cancer progression risk. Elahere, developed by ImmunoGen and acquired by AbbVie, targets folate receptor alpha.

The article focuses on the FDA approval of Duvyzat (givinostat) as an oral nonsteroidal drug to treat Duchenne muscular dystrophy (DMD), marking the first approval of its kind for patients with all genetic variants of DMD, with anticipated availability in the third quarter of 2024. Developed by Italfarmaco in collaboration with Telethon and Duchenne Parent Project (Italy), Duvyzat works as a histone deacetylase (HDAC) inhibitor to alleviate inflammation and muscle loss associated with DMD.

The article highlights recently implemented or ongoing advances from the pharmacopoeias, along with pharmacopoeias' response to the COVID-19 pandemic. It mentions European Directorate for the Quality of Medicines and HealthCare (EDQM) made texts from the Ph.Eur. for vaccine developers available free on their website, along with a guidance on recombinant viral vectored vaccines, which was not available before the pandemic.